Adaptive TCR has changed its name to Adaptive Biotechnologies, the company said this week.
The Seattle-based firm provides next-generation sequencing assays under the brand name ImmunoSeq to analyze the adaptive immune system.
Last summer, it raised $5.8 million in a Series B round to grow its services and invest in clinical applications (CSN 6/15/2011).
According to the company's CEO, Chad Robins, the name change better reflects "the full nature and potential" of its products and services, which include T-cell and B-cell receptor sequencing as well as the development of clinical applications for the diagnosis and prognosis of cancer.
Clinical applications include monitoring minimal residual disease in blood-based cancers, more accurate measurements for immune reconstitution after transplantation, and direct measurement of tumor-infiltrating lymphocytes as a prognostic indicator of ovarian cancer. The company is also developing threshold tests to stratify patients into clinical trials, and to predict their response to therapeutics and vaccines.